189 related articles for article (PubMed ID: 37072171)
1. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.
Pepe F; Guerini-Rocco E; Fassan M; Fusco N; Vacirca D; Ranghiero A; Venetis K; Rappa A; Taormina SV; Russo G; Rebellato E; Munari G; Moreno-Manuel A; De Angelis C; Zamagni C; Valabrega G; Malapelle U; Troncone G; Barberis M; Iaccarino A
J Clin Pathol; 2024 Jun; 77(7):478-485. PubMed ID: 37072171
[TBL] [Abstract][Full Text] [Related]
2. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
3. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
Roma C; Esposito Abate R; Sacco A; Califano D; Arenare L; Bergantino F; Pisano C; Cecere SC; Scambia G; Lorusso D; Artioli G; Tasca G; Spina A; Russo D; Gadducci A; De Angelis C; Bologna A; Marchini S; Capoluongo ED; Perrone F; Pignata S; Normanno N
Eur J Cancer; 2024 Jul; 206():114127. PubMed ID: 38797038
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
5. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
6. A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.
Guarischi-Sousa R; Kroll JE; Bonaldi A; Pierry PM; Villela D; Souza CA; Silva JS; Bürger MC; Oliveira FA; de Paula MG; Meliso FM; de Almeida LG; Monfredini PM; de Oliveira AG; Milanezi F; Scapulatempo-Neto C; Yamamoto GL
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958189
[TBL] [Abstract][Full Text] [Related]
7. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
8. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
10. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.
Pfarr N; von Schwarzenberg K; Zocholl D; Merkelbach-Bruse S; Siemanowski J; Mayr EM; Herold S; Kleo K; Heukamp LC; Willing EM; Menzel M; Lehmann U; Bartels S; Chakraborty S; Baretton G; Demes MC; Döring C; Kazdal D; Budczies J; Rad R; Wild P; Christinat Y; McKee T; Schirmacher P; Horst D; Büttner R; Stenzinger A; Sehouli J; Vollbrecht C; Hummel M; Braicu EI; Weichert W;
JCO Precis Oncol; 2024 Mar; 8():e2300348. PubMed ID: 38513168
[TBL] [Abstract][Full Text] [Related]
11. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
13. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy.
Rognoni C; Lorusso D; Costa F; Armeni P
Adv Ther; 2024 Apr; 41(4):1385-1400. PubMed ID: 38329713
[TBL] [Abstract][Full Text] [Related]
15. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
16. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
17. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C; Romey M; Swedlund B; Hattesohl A; Teply-Szymanski J; Kommoss S; Kaiser K; Staebler A; du Bois A; Grass A; Knappmeyer C; Heitz F; Solimeno C; Ebel T; Harter P; Marmé F; Jank P; Gaiser T; Neff C; Wagner U; Timms KM; Rodepeter F
J Mol Diagn; 2022 Dec; 24(12):1254-1263. PubMed ID: 36191839
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]